Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: A retrospective analysis of 17 patients

British Journal of Dermatology

Volumn 164, Issue 3, 2011, Pages 645-647

  Prignano, F ^a   Ricceri, F ^a   Pescitelli, L ^a   Zanieri, F ^a   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; ETANERCEPT;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONCURRENT INFECTION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SIDE EFFECT; VIRUS LOAD;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TRANSAMINASES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 79952367859     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10140.x     Document Type: Article

References (12)

1. Domm S, Cinatl J, Mrowietz U,. The impact of treatment with tumour necrosis factor alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-28.
2. Prignano F, Pescitelli L, Ricceri F, Lotti T,. Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. J Eur Acad Dermatol Venereol 2010; 24: 555-60.
3. Parke FA, Reveille JD,. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Care Res 2004; 51: 800-4. (Pubitemid 39372039)
4. Peterson JR, Hsu FC, Simkin PA, Wener MH,. Effect of tumor necrosis alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 2078-82.
5. Magliocco MA, Gottlieb AB,. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580-4. (Pubitemid 39278078)
6. Alter MJ,. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 (Suppl. 1): S64-9. (Pubitemid 37222649)
7. Lavancy D, McMahon B,. Worldwide prevalence and prevention of hepatitis C. In: Hepatitis C (, Liang TJ, Hoofnagle JH, eds). San Diego, CA: Academic Press, 2000; 186-201.
8. Ellerin T, Rubin RH, Weinblatt ME,. Infections and antitumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-22. (Pubitemid 37409310)
9. Calabrese LH, Zein N, Vassilopoulos D,. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis B, hepatitis C, and HIV infection. Ann Rheum Dis 2004; 63 (Suppl. II): ii18-24. (Pubitemid 39424653)
10. Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-91. (Pubitemid 29071178)
11. Marinos G, Naoumov NV, Rossol S, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108: 1453-63.
12. Ghavami S, Hashemi M, Kadkhoda K, et al. Apoptosis in liver diseases-detection and therapeutic applications. Med Sci Monit 2005; 11: RA337-45. (Pubitemid 41695499)